Keywords
Eosinophils
Biomarkers
Submitted : 2024-06-23
Accepted : 2024-07-08
Published : 2024-07-23
Abstract
Chronic obstructive pulmonary disease (COPD) accounts for one of the major health and economic burdens worldwide. As a heterogeneous disease, the underlying inflammatory pattern of COPD differs from the previously thought neutrophil-dominated inflammation, with eosinophilic inflammation occupying approximately one third of stable COPD. Although the eosinophil (EOS) threshold associated with clinical relevance in patients with COPD is currently debated, eosinophil count can be used as a biomarker to guide treatment and to assess the risk of acute exacerbations of COPD, the efficacy of inhaled corticosteroids, and clinical outcomes. The purpose of this review is to describe the biological characteristics of eosinophils and the related research progress as clinical biomarkers.
References
Hurst JR, Vestbo J, Anzueto A, et al., 2010, Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med, 363(12): 1128–1138.
Kaur D, Mehta RL, Jarrett H, et al., 2023, Phase III, Two Arm, Multi-Centre, Open Label, Parallel-Group Randomised Designed Clinical Investigation of the Use of a Personalised Early Warning Decision Support System to Predict and Prevent Acute Exacerbations of Chronic Obstructive Pulmonary Disease: ‘Predict & Prevent AECOPD’ - Study Protocol. BMJ Open, 13(3): e61050.
Toraldo DM, Rizzo E, Conte L, 2022, Effects of Inhaled Corticosteroids (ICS) on Lung Microbiota and Local Immune Response in Long-Term Treatment of Chronic Obstructive Pulmonary Disease (COPD): Utility of Titration and Therapeutic Index. Naunyn Schmiedebergs Arch Pharmacol, 395(7): 849–858.
Singh D, Agusti A, Anzueto A, et al., 2019, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The GOLD Science Committee Report 2019. Eur Respir J, 53(5): 1900164.
Knuplez E, Kienzl M, Trakaki A, et al., 2021, The Anti-Parasitic Drug Miltefosine Suppresses Activation of Human Eosinophils and Ameliorates Allergic Inflammation in Mice. Br J Pharmacol, 178(5): 1234–1248.
Palacionyte J, Januskevicius A, Vasyle E, et al., 2022, IL-5 and GM-CSF, But Not IL-3, Promote the Proliferative Properties of Inflammatory-Like and Lung Resident-Like Eosinophils in the Blood of Asthma Patients. Cells, 11(23): 3804.
Li C, Ward LA, Nguyen A, et al., 2022, Neonatal LTbetaR Signaling Is Required for the Accumulation of Eosinophils in the Inflamed Adult Mesenteric Lymph Node. Mucosal Immunol, 15(3): 418–427.
Xenakis JJ, Howard ED, Smith KM, et al., 2018, Resident Intestinal Eosinophils Constitutively Express Antigen Presentation Markers and Include Two Phenotypically Distinct Subsets of Eosinophils. Immunology, 154(2): 298–308.
Yi S, Zhai J, Niu R, et al., 2018, Eosinophil Recruitment Is Dynamically Regulated by Interplay Among Lung Dendritic Cell Subsets After Allergen Challenge. Nat Commun, 9(1): 3879.
Pfeffer PE, Ali N, Murray R, et al., Comparative Effectiveness of Anti-IL5 and Anti-IgE Biologic Classes in Patients with Severe Asthma Eligible for Both. Allergy, 78(7): 1934–1948.
Asosingh K, Hanson JD, Cheng G, et al., 2010, Allergen-Induced, Eotaxin-Rich, Proangiogenic Bone Marrow Progenitors: A Blood-Borne Cellular Envoy for Lung Eosinophilia. J Allergy Clin Immunol, 125(4): 918–925.
Liu LY, Mathur SK, Sedgwick JB, et al., 2006, Human Airway and Peripheral Blood Eosinophils Enhance Th1 and Th2 Cytokine Secretion. Allergy, 61(5): 589–597.
Smith SG, Chen R, Kjarsgaard M, et al., 2016, Increased Numbers of Activated Group 2 Innate Lymphoid Cells in the Airways of Patients with Severe Asthma and Persistent Airway Eosinophilia. J Allergy Clin Immunol, 137(1): 75–86.
Ibrahim B, Achour D, Zerimech F, et al., 2023, Plasma Thymic Stromal Lymphopoietin (TSLP) in Adults with Non-Severe Asthma: The EGEA Study. Thorax, 78(2): 207–210.
Moller DL, Kielsen K, Nielsen CH, et al., 2022, Thymic Stromal Lymphopoietin Levels After Allogeneic Hematopoietic Stem Cell Transplantation. Immunopharmacol Immunotoxicol, 44(6): 1004–1012.
Rutgers SR, Timens W, Kaufmann HF, et al., 2000, Comparison of Induced Sputum with Bronchial Wash, Bronchoalveolar Lavage and Bronchial Biopsies in COPD. Eur Respir J, 15(1): 109–115.
Meyer KC, Raghu G, Baughman RP, et al., 2012, An Official American Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease. Am J Respir Crit Care Med, 185(9): 1004–1014.
Pavord ID, Lettis S, Anzueto A, et al., 2016, Blood Eosinophil Count and Pneumonia Risk in Patients with Chronic Obstructive Pulmonary Disease: A Patient-Level Meta-Analysis. Lancet Respir Med, 4(9): 731–741.
Watz H, Tetzlaff K, Wouters EF, et al., 2016, Blood Eosinophil Count and Exacerbations in Severe Chronic Obstructive Pulmonary Disease After Withdrawal of Inhaled Corticosteroids: A Post-Hoc Analysis of the WISDOM Trial. Lancet Respir Med, 4(5): 390–398.
Basanta M, Ibrahim B, Dockry R, et al., 2012, Exhaled Volatile Organic Compounds for Phenotyping Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study. Respir Res, 13(1): 72.
Avdeev SN, Trushenko NV, Merzhoeva ZM, et al., 2019, Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease. Ter Arkh, 91(10): 144–152.
Yang Z, Cui M, Zhang X, et al., 2020, Identification of Symptom Clusters and Their Influencing Factors in Subgroups of Chinese Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. J Pain Symptom Manage, 60(3): 559–567.
Pavord ID, Lettis S, Locantore N, et al., 2016, Blood Eosinophils and Inhaled Corticosteroid/Long-Acting Beta-2 Agonist Efficacy in COPD. Thorax, 71(2): 118–125.
Landis S, Suruki R, Maskell J, et al., 2018, Demographic and Clinical Characteristics of COPD Patients at Different Blood Eosinophil Levels in the UK Clinical Practice Research Datalink. COPD, 15(2): 177–184.
Oshagbemi OA, Burden AM, Braeken D, et al., 2017, Stability of Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts. Am J Respir Crit Care Med, 195(10): 1402–1404.
Kim VL, Coombs NA, Staples KJ, et al., 2017, Impact and Associations of Eosinophilic Inflammation in COPD: Analysis of the AERIS Cohort. Eur Respir J, 50(4): 1700853.
Schumann DM, Tamm M, Kostikas K, et al., 2019, Stability of the Blood Eosinophilic Phenotype in Stable and Exacerbated COPD. Chest, 156(3): 456–465.
Van Rossem I, Vandevoorde J, Hanon S, et al., 2020, The Stability of Blood Eosinophils in Stable Chronic Obstructive Pulmonary Disease: A Retrospective Study in Belgian primary care. BMC Pulm Med, 20(1): 200.
Vedel-Krogh S, Nielsen SF, Lange P, et al., 2016, Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med, 193(9): 965–974.
Bafadhel M, Mckenna S, Terry S, et al., 2011, Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Identification of Biologic Clusters and Their Biomarkers. Am J Respir Crit Care Med, 184(6): 662–671.
Siddiqui SH, Guasconi A, Vestbo J, et al., 2015, Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 192(4): 523–525.
Yun JH, Lamb A, Chase R, et al., 2018, Blood Eosinophil Count Thresholds and Exacerbations in Patients with Chronic Obstructive Pulmonary Disease. J Allergy Clin Immunol, 141(6): 2037–2047.
Bafadhel M, Peterson S, De Blas MA, et al., 2018, Predictors of Exacerbation Risk and Response to Budesonide in Patients with Chronic Obstructive Pulmonary Disease: A Post-hoc analysis of Three Randomised Trials. Lancet Respir Med, 6(2): 117–126.
Hastie AT, Martinez FJ, Curtis JL, et al., 2017, Association of Sputum and Blood Eosinophil Concentrations with Clinical Measures of COPD Severity: An Analysis of the SPIROMICS Cohort. Lancet Respir Med, 5(12): 956–967.
Zysman M, Deslee G, Caillaud D, et al., 2017, Relationship Between Blood Eosinophils, Clinical Characteristics, and Mortality in Patients with COPD. Int J Chron Obstruct Pulmon Dis, (12): 1819–1824.
Bafadhel M, Rabe KF, Martinez FJ, et al., 2022, Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. Int J Chron Obstruct Pulmon Dis, (17): 3061–3073.
Suissa S, Dell’aniello S, Ernst P, 2018, Comparative Effectiveness of LABA-ICS Versus LAMA as Initial Treatment in COPD Targeted by Blood Eosinophils: A Population-Based Cohort Study. Lancet Respir Med, 6(11): 855–862.
Wedzicha JA, Banerji D, Chapman KR, et al., 2016, Indacaterol-Glycopyrronium Versus Salmeterol-Fluticasone for COPD. N Engl J Med, 374(23): 2222–2234.
Barnes NC, Sharma R, Lettis S, et al., 2016, Blood Eosinophils as a Marker of Response to Inhaled Corticosteroids in COPD. Eur Respir J, 47(5): 1374–1382.
Roche N, Chapman KR, Vogelmeier CF, et al., 2017, Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. Am J Respir Crit Care Med, 195(9): 1189–1197.
Hospers JJ, Schouten JP, Weiss ST, et al., 2000, Eosinophilia is Associated with Increased All-Cause Mortality After a Follow-Up of 30 Years in a General Population Sample. Epidemiology, 11(3): 261–268.
Saltürk C, Karakurt Z, Adiguzel N, et al., 2015, Does Eosinophilic COPD Exacerbation Have a Better Patient Outcome Than Non-Eosinophilic in the Intensive Care Unit? Int J Chron Obstruct Pulmon Dis, (10): 1837–1846.
Bafadhel M, Greening NJ, Harvey-Dunstan TC, et al., 2016, Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. Chest, 150(2): 320–328.